Q1 Earnings Forecast for BMY Issued By William Blair

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research note issued to investors on Monday, November 18th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will post earnings of $1.75 per share for the quarter. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.93 per share. William Blair also issued estimates for Bristol-Myers Squibb's Q2 2025 earnings at $1.92 EPS, Q3 2025 earnings at $2.04 EPS, Q4 2025 earnings at $1.80 EPS, FY2025 earnings at $7.51 EPS, FY2026 earnings at $7.19 EPS and FY2027 earnings at $7.46 EPS.

Several other equities research analysts have also weighed in on the company. Citigroup upped their price objective on Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a "neutral" rating in a research note on Tuesday, November 12th. StockNews.com raised Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Monday, July 29th. Jefferies Financial Group boosted their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a "hold" rating in a report on Wednesday, August 28th. UBS Group boosted their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a "neutral" rating in a report on Wednesday, October 9th. Finally, Barclays upped their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an "underweight" rating in a report on Monday, October 7th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $54.07.

Bristol-Myers Squibb Stock Down 0.2 %

Shares of NYSE:BMY traded down $0.10 on Wednesday, reaching $58.13. The company had a trading volume of 4,773,873 shares, compared to its average volume of 14,397,505. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The stock has a 50-day moving average price of $53.08 and a 200 day moving average price of $47.47. The stock has a market capitalization of $117.90 billion, a P/E ratio of -16.21, a P/E/G ratio of 15.08 and a beta of 0.44. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion during the quarter, compared to analysts' expectations of $11.26 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The business's quarterly revenue was up 8.4% compared to the same quarter last year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.13%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -66.85%.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction dated Friday, November 1st. The shares were bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares of the company's stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BMY. Bessemer Group Inc. lifted its position in shares of Bristol-Myers Squibb by 16.3% in the 1st quarter. Bessemer Group Inc. now owns 159,066 shares of the biopharmaceutical company's stock worth $8,625,000 after purchasing an additional 22,286 shares during the period. Lake Street Advisors Group LLC lifted its position in shares of Bristol-Myers Squibb by 54.7% in the 1st quarter. Lake Street Advisors Group LLC now owns 13,530 shares of the biopharmaceutical company's stock worth $734,000 after purchasing an additional 4,784 shares during the period. Ossiam lifted its position in shares of Bristol-Myers Squibb by 31.7% in the 1st quarter. Ossiam now owns 88,183 shares of the biopharmaceutical company's stock worth $4,782,000 after purchasing an additional 21,234 shares during the period. Payden & Rygel Investment Group purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $206,000. Finally, EntryPoint Capital LLC lifted its position in Bristol-Myers Squibb by 113.0% during the 1st quarter. EntryPoint Capital LLC now owns 3,501 shares of the biopharmaceutical company's stock valued at $190,000 after acquiring an additional 1,857 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.